share_log

康寧傑瑞製藥-B：自願公告 - 與思路迪醫藥及GLENMARK就KN035達成的許可協議

ALPHAMAB-B: VOLUNTARY ANNOUNCEMENT - LICENSE AGREEMENT WITH 3D MEDICINES AND GLENMARK FOR KN035

香港交易所 ·  Jan 24 19:05
Summary by Moomoo AI
康寧杰瑞制藥-B（ALPHAMAB ONCOLOGY）宣布與思路迪醫藥及Glenmark就其自主研發的抗PD-L1單域抗體Fc融合蛋白KN035（恩沃利單抗注射液，商標名稱：恩維達®）達成獨家許可協議。該協議於2024年1月24日簽訂，授予Glenmark在特定地區內開發及商業化KN035的獨家許可。根據協議，康寧杰瑞將收取最高達700.8百萬美元的預付款及里程碑付款，以及基於KN035淨銷售額的特許權使用費。康寧杰瑞相信此合作將有助於KN035在相關市場的快速商業化，並對其商業化進程產生積極影響。Glenmark為一家全球製藥公司，專注於呼吸道、皮膚及腫瘤學等治療領域，而思路迪醫藥則專注於開發免疫腫瘤藥物。康寧杰瑞表示，此次合作將利用Glenmark的資源及團隊，加速KN035在指定地區的市場佔有率。
康寧杰瑞制藥-B（ALPHAMAB ONCOLOGY）宣布與思路迪醫藥及Glenmark就其自主研發的抗PD-L1單域抗體Fc融合蛋白KN035（恩沃利單抗注射液，商標名稱：恩維達®）達成獨家許可協議。該協議於2024年1月24日簽訂，授予Glenmark在特定地區內開發及商業化KN035的獨家許可。根據協議，康寧杰瑞將收取最高達700.8百萬美元的預付款及里程碑付款，以及基於KN035淨銷售額的特許權使用費。康寧杰瑞相信此合作將有助於KN035在相關市場的快速商業化，並對其商業化進程產生積極影響。Glenmark為一家全球製藥公司，專注於呼吸道、皮膚及腫瘤學等治療領域，而思路迪醫藥則專注於開發免疫腫瘤藥物。康寧杰瑞表示，此次合作將利用Glenmark的資源及團隊，加速KN035在指定地區的市場佔有率。
Alphamab Oncology announced an exclusive licensing agreement with Sludi Pharmaceuticals and Glenmark for its independently developed anti-PD-L1 single-domain antibody Fc fusion protein KN035 (Envolone Anti-Injection, trademark: Envida®). The agreement, signed on 24 January 2024, grants Glenmark an exclusive licence to develop and commercialise KN035 in specific regions. Under the agreement, Corning will collect up to $700.8 million in upfront and milestone payments, as well as royalty fees based on KN035 net sales. CorningJerry believes this collaboration will contribute to the rapid commercialization of KN035 in related markets and have a positive impact on its commercialization process. Glenmark is a global pharmaceutical company focused on treatments such as respiratory, dermatology and oncology, while Sludi Pharmaceuticals focuses on the development of immuno-oncology drugs. Corning said the collaboration will leverage Glenmark's resources and team to accelerate KN035's market share in select regions.
Alphamab Oncology announced an exclusive licensing agreement with Sludi Pharmaceuticals and Glenmark for its independently developed anti-PD-L1 single-domain antibody Fc fusion protein KN035 (Envolone Anti-Injection, trademark: Envida®). The agreement, signed on 24 January 2024, grants Glenmark an exclusive licence to develop and commercialise KN035 in specific regions. Under the agreement, Corning will collect up to $700.8 million in upfront and milestone payments, as well as royalty fees based on KN035 net sales. CorningJerry believes this collaboration will contribute to the rapid commercialization of KN035 in related markets and have a positive impact on its commercialization process. Glenmark is a global pharmaceutical company focused on treatments such as respiratory, dermatology and oncology, while Sludi Pharmaceuticals focuses on the development of immuno-oncology drugs. Corning said the collaboration will leverage Glenmark's resources and team to accelerate KN035's market share in select regions.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more